Strok@lliance is pleased to announce the acquisition of ISO 9001 certification based on the standard from 2015.
Through an internal and external Audit of the OFC (the French Certification Organization): quality assurance, control and monitoring procedures have been carried out to attest to the quality of our services.
By being accredited, our company is insuring the customers to meet their expectations by the quality of its management system in the following areas: consulting, advising and expertise of studies in the field of in vitro and in vivo preclinical research.

Impact of Bradykinin Generation During Thrombolysis in Ischemic Stroke

A very interesting review have been published by our Caen academic partner (PhIND unit, Université de Caen Normandie / INSERM ) concerning the current evidence linking tPA mediated thrombolysis, bradykinin generation and potential subsequent neurovascular damages. While tPA is an important pharmacological tool for acute stroke management, this clot buster also promotes hemorrhagic transformation, symptomatic cerebral edema and angioedema. Preclinical and clinical evidence suggests that intravenous thrombolysis generates large amounts of bradykinin, a peptide with potent pro-inflammatory, and pro-edematous effects. Thus, this tPA-induced generation of bradykinin is a potential target to improve neurological outcome after thrombolysis.

Link to the article

JOIN US!

 

Strok@lliance is growing to provide its customers with high level and original services in preclinical stroke studies.

You have now the opportunity to join a young and dynamic team looking for challenge in a high level scientific and technologic environment !

 

Strok@lliance invites applications from eligible candidates for recruitment of a Scientific Laboratory Technician in stroke preclinical testing.

The company is looking for individuals who wants to contribute their skills to provide excellent work in a challenging and rewarding environment.

 

Find the application details here.